Literature DB >> 27587619

Characterization of Prostate Cancer in a Functional Eunuch.

John J Stocking1, Michael V Fiandalo1, Elena A Pop1, John H Wilton1, Gissou Azabdaftari1, James L Mohler1.   

Abstract

BACKGROUND: Eunuchs rarely, if ever, develop prostate cancer (CaP). This article reports on a 62-year-old functional eunuch from prepubertal mumps orchitis who developed clinically localized CaP.
METHODS: Serum and CaP and benign prostate tissue androgen levels were measured using a validated liquid chromatography-tandem mass spectrometry assay. The assay measures testosterone; dihydrotestosterone (DHT); the adrenal androgens, androstenedione and dehydroepiandrosterone; and the androgen metabolites, androsterone and androstanedione. Gene and protein expression levels of androgen metabolism enzymes, and androgen receptor and androgen-regulated genes were measured using quantitative reverse-transcription polymerase chain reaction and immunohistochemistry, respectively.
RESULTS: Intracrine androgen metabolism produced tissue DHT when serum and tissue testosterone levels were castrate and undetectable, respectively. Androgen receptor, androgen-regulated, and androgen metabolism enzyme genes were expressed but at lower levels in CaP than benign tissues.
CONCLUSIONS: DHT was synthesized using the primary backdoor androgen metabolism pathway and not using androstenedione or dehydroepiandrosterone via the frontdoor or secondary backdoor pathways.
Copyright © 2016 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2016        PMID: 27587619      PMCID: PMC5749417          DOI: 10.6004/jnccn.2016.0116

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  31 in total

1.  Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts.

Authors:  J D Wilson; C Roehrborn
Journal:  J Clin Endocrinol Metab       Date:  1999-12       Impact factor: 5.958

2.  The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens.

Authors:  Burkhard Helpap; Lars Egevad
Journal:  Virchows Arch       Date:  2006-11-08       Impact factor: 4.064

3.  The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different.

Authors:  G P Kraan; R P Dullaart; J J Pratt; B G Wolthers; N M Drayer; R De Bruin
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

Review 4.  Unusual properties of the cytochrome P450 superfamily.

Authors:  David C Lamb; Michael R Waterman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-01-06       Impact factor: 6.237

5.  Androgenic biomarker prof|ling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry.

Authors:  John H Wilton; Mark A Titus; Eleni Efstathiou; Gerald J Fetterly; James L Mohler
Journal:  Prostate       Date:  2014-05       Impact factor: 4.104

6.  Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.

Authors:  Mark A Titus; Michael J Schell; Fred B Lih; Kenneth B Tomer; James L Mohler
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

7.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

Authors:  C Huggins; C V Hodges
Journal:  CA Cancer J Clin       Date:  1972 Jul-Aug       Impact factor: 508.702

8.  Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.

Authors:  Kai-Hsiung Chang; Rui Li; Mahboubeh Papari-Zareei; Lori Watumull; Yan Daniel Zhao; Richard J Auchus; Nima Sharifi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-27       Impact factor: 11.205

9.  Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.

Authors:  James L Mohler; Mark A Titus; Suxia Bai; Brian J Kennerley; Fred B Lih; Kenneth B Tomer; Elizabeth M Wilson
Journal:  Cancer Res       Date:  2011-02-08       Impact factor: 12.701

10.  Racial differences in prostate androgen levels in men with clinically localized prostate cancer.

Authors:  James L Mohler; Kris E Gaston; Dominic T Moore; Michael J Schell; Brian L Cohen; Catharina Weaver; Peter Petrusz
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

View more
  2 in total

1.  Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.

Authors:  Michael V Fiandalo; John H Wilton; Krystin M Mantione; Carol Wrzosek; Kristopher M Attwood; Yue Wu; James L Mohler
Journal:  Prostate       Date:  2017-12-01       Impact factor: 4.104

2.  Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade.

Authors:  Michael V Fiandalo; John J Stocking; Elena A Pop; John H Wilton; Krystin M Mantione; Yun Li; Kristopher M Attwood; Gissou Azabdaftari; Yue Wu; David S Watt; Elizabeth M Wilson; James L Mohler
Journal:  Oncotarget       Date:  2018-01-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.